ResMed Inc. (RMD.AX)
| Previous close | 28.74 |
| Open | 30.91 |
| Bid | 31.13 x 51100 |
| Ask | 31.55 x 25600 |
| Day's range | 30.54 - 31.58 |
| 52-week range | 21.14 - 36.37 |
| Volume | |
| Avg. volume | 2,231,311 |
| Market cap | 46.333B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 33.87 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.29 (0.92%) |
| Ex-dividend date | 07 Feb 2024 |
| 1y target est | N/A |
- GlobeNewswire
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up
- GlobeNewswire
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:http://investor.resmed.com • Da
- GlobeNewswire
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
36,000 people across 17 markets responded to the company’s fourth annual survey.40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality. SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sl
